Clinical Trial Update: Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg [Phase 3]

View source ↗

Summary

Open-label safety extension study for LMIS 50 mg in patients with prostatic neoplasms, completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms

Drugs mentioned

• LMIS 50 mg (LMIS 50 mg)

Snippet

Sponsor: Foresee Pharmaceuticals Co., Ltd. | Conditions: Prostatic Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2018-09-12